Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG ("Araris") today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based ...

The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

Transcenta Holding-B (06628.HK) announced that it presented preclinical data at the 2026 AACR Annual Meeting highlighting its ...

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Researchers use new antibody–drug conjugates that combine a CD4 mimic with neutralizing antibodies to inhibit human immunodeficiency virus (HIV) entry into host cells. New antibody–drug conjugates ...